Q1 2026 · 13F-HR
TCG Crossover Management, LLCholdings as filed
Filed 2026-05-15 · accession 0001214659-26-006367
$3.50B
Reported value
49
Positions
2026-03-31
Period end
The Brief · TCG Crossover Management, LLC · Q1 2026
AI · grounded in 13F
TCG Crossover Management, LLC exited its position in RAPT for a reduction of $87.5M. The fund established new positions in BCRX for $104.9M, VOR for $96.5M, and DISC MEDICINE INC for $85.8M. Additionally, the manager closed its position in EYPT for $65.3M and increased its stake in MIRM by 1611.6%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 00370M103 | ABVX | ABIVAX SA AMERICAN DEPOSITARY SHARES | $721.7M | 20.6% | 6,481,085 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $248.4M | 7.11% | 3,670,206 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $220.3M | 6.30% | 10,531,071 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $190.4M | 5.45% | 4,946,894 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $170.3M | 4.87% | 4,286,480 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $140.7M | 4.03% | 1,676,624 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $124.4M | 3.56% | 3,248,980 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $110.7M | 3.17% | 4,457,988 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $104.9M | 3.00% | 11,020,968 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $98.1M | 2.81% | 1,062,049 | Common | SOLE |
| 929033207 | VOR | VOR BIOPHARMA INC | $96.5M | 2.76% | 5,673,078 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $95.9M | 2.74% | 1,900,582 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $86.8M | 2.48% | 6,243,812 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $85.8M | 2.45% | 1,341,862 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $83.7M | 2.39% | 4,615,144 | Common | SOLE |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $76.0M | 2.18% | 4,622,151 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $67.5M | 1.93% | 12,362,205 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $56.1M | 1.60% | 576,473 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $55.1M | 1.58% | 1,445,538 | Common | SOLE |
| 50180M108 | LBRX | LB PHARMACEUTICALS INC | $45.3M | 1.30% | 1,839,489 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $42.9M | 1.23% | 1,473,101 | Common | SOLE |
| H0036K147 | ADCT | ADC THERAPEUTICS SA | $42.7M | 1.22% | 11,390,175 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $42.5M | 1.22% | 4,273,356 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $40.3M | 1.15% | 5,250,000 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $39.2M | 1.12% | 4,631,317 | Common | SOLE |
| 15673T100 | IPSC | CENTURY THERAPEUTICS INC | $39.0M | 1.12% | 17,754,430 | Common | SOLE |
| 878972108 | TECX | TECTONIC THERAPEUTIC INC | $37.2M | 1.07% | 1,204,891 | Common | SOLE |
| 46489V302 | CATX | PERSPECTIVE THERAPEUTICS INC | $33.0M | 0.94% | 7,915,567 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $29.6M | 0.85% | 2,452,138 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $28.9M | 0.83% | 2,287,500 | Common | SOLE |
| 00166B105 | ALXO | ALX ONCOLOGY HOLDINGS INC | $26.1M | 0.75% | 13,011,849 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS HOLDING CO LLC | $25.3M | 0.72% | 2,387,461 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $24.9M | 0.71% | 1,789,617 | Common | SOLE |
| 00860C102 | AGMB | AGOMAB THERAPEUTICS NV | $21.5M | 0.62% | 2,053,233 | Common | SOLE |
| 014442107 | ALEC | ALECTOR INC | $21.5M | 0.62% | 10,000,000 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $19.4M | 0.56% | 650,000 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $16.0M | 0.46% | 3,033,560 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA TECHNOLOGIES INC | $15.2M | 0.44% | 403,048 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $14.0M | 0.40% | 1,647,752 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $11.0M | 0.32% | 738,383 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $7.3M | 0.21% | 405,365 | Common | SOLE |
| 61023L207 | MNPR | MONOPAR THERAPEUTICS INC | $7.2M | 0.21% | 132,103 | Common | SOLE |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $7.0M | 0.20% | 2,682,696 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $6.8M | 0.19% | 140,411 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $5.8M | 0.17% | 406,786 | Common | SOLE |
| 500946108 | KRRO | KORRO BIO INC | $4.7M | 0.13% | 416,301 | Common | SOLE |
| 04746L203 | LONA | LEONABIO INC | $4.7M | 0.13% | 464,398 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $1.6M | 0.05% | 181,063 | Common | SOLE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $1.5M | 0.04% | 2,676,580 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.